Celadon Pharmaceuticals Plc Stock price

Equities

CEL

GB00BDQYGP38

Pharmaceuticals

Delayed London S.E. 08:20:03 2024-03-28 am EDT 5-day change 1st Jan Change
81.84 GBX -0.79% Intraday chart for Celadon Pharmaceuticals Plc -11.52% -28.83%
Sales 2021 - Sales 2022 0.02 Capitalization 31.14M
Net income 2021 - Net income 2022 -17M EV / Sales 2021 * -
Net cash position 2021 4.46M Net cash position 2022 429K EV / Sales 2022 1,279,759,792 x
P/E ratio 2021 *
-
P/E ratio 2022
-1.71 x
Employees 24
Yield 2021 *
-
Yield 2022
-
Free-Float 26.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.79%
1 week-11.52%
Current month-18.16%
1 month-23.87%
3 months-28.83%
6 months-31.80%
Current year-28.83%
More quotes
1 week
80.00
Extreme 80
95.00
1 month
80.00
Extreme 80
110.00
Current year
80.00
Extreme 80
120.00
1 year
73.44
Extreme 73.437
189.00
3 years
47.50
Extreme 47.5
189.00
5 years
47.50
Extreme 47.5
189.00
10 years
47.50
Extreme 47.5
189.00
More quotes
Managers TitleAgeSince
Founder 55 17-12-31
Director of Finance/CFO 46 23-01-16
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 62 -
Chairman 64 22-03-27
Director/Board Member 65 22-03-27
More insiders
Date Price Change Volume
24-03-28 81.84 -0.79% 3 072
24-03-27 82.5 0.00% 5,143
24-03-26 82.5 -8.33% 35,681
24-03-25 90 +2.86% 21,533
24-03-22 87.5 -5.41% 26,337

Delayed Quote London S.E., March 28, 2024 at 08:20 am EDT

More quotes
Celadon Pharmaceuticals Plc is a United Kingdom-based pharmaceutical company. The Company is engaged in research, cultivation, manufacturing and supply of cannabinoid-based medicines. The Company is focused on growing indoor hydroponic cannabis initially for the chronic pain market. It is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions, such as autism and multiple sclerosis. The Company's facility comprises an indoor, closed-loop hydroponic system to ensure cannabis plants are cultivated under a highly specific climate, light and with irrigation control. The Company's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.825 GBP
Average target price
2.35 GBP
Spread / Average Target
+184.85%
Consensus
  1. Stock
  2. Equities
  3. Stock Celadon Pharmaceuticals Plc - London S.E.